Upregulated Claudin-18.2 Is a Poor Prognostic Indicator for Rectal Cancer Patients Undergoing Preoperative Concurrent Chemoradiotherapy
Elevated CLDN18.2 expression is associated with adverse clinical outcomes and pathological features, yet suggests a more unfavorable treatment response in rectal cancer patients undergoing CCRT, indicating its potential as a biomarker.
Authors
- Ching‐Chieh Yang (ORCID: https://orcid.org/0000-0003-3823-4673)
- Sung-Wei Lee
- Yufeng Tian (ORCID: https://orcid.org/0000-0002-6814-7071)
- Yow‐Ling Shiue (ORCID: https://orcid.org/0000-0003-0798-5028)
- Wan‐Shan Li (ORCID: https://orcid.org/0000-0001-6679-4868)
- Yu‐Hsuan Kuo (ORCID: https://orcid.org/0000-0003-1249-6579)
- Cheng‐Yi Lin
- Han-Ping Hsu
- Hung‐Chang Wu
- Chia‐Lin Chou
Institutions
- Chung Hwa University of Medical Technology (TW)
- National Sun Yat-sen University (TW)
- Chi Mei Medical Center (TW)
- Chia Nan University of Pharmacy and Science (TW)
Publication Details
- Journal
- Oncology
- Published
- 2025-07-04
- DOI
- https://doi.org/10.1159/000547239
- Primary Topic
- Barrier Structure and Function Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00